Shares of Aytu BioPharma Inc. (NASDAQ:AYTU – Get Free Report) have received a consensus rating of “Hold” from the five research firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $8.60.
Several research analysts have recently commented on the stock. Lake Street Capital lowered shares of Aytu BioPharma from a “buy” rating to a “hold” rating and set a $2.70 price target on the stock. in a research note on Tuesday. Weiss Ratings lowered shares of Aytu BioPharma from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, October 6th. Zacks Research lowered shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Finally, Citigroup restated a “positive” rating on shares of Aytu BioPharma in a research note on Tuesday, September 22nd.
Read Our Latest Analysis on AYTU
Aytu BioPharma Price Performance
Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06. The firm had revenue of $14.84 million during the quarter, compared to analysts’ expectations of $13.27 million. Aytu BioPharma had a negative net margin of 24.76% and a negative return on equity of 56.54%. As a group, research analysts expect that Aytu BioPharma will post -0.16 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC bought a new position in Aytu BioPharma in the 2nd quarter worth $2,336,646. Stonepine Capital Management LLC acquired a new position in Aytu BioPharma during the 2nd quarter worth $1,962,780. AWM Investment Company Inc. acquired a new position in Aytu BioPharma during the 2nd quarter worth $1,332,000. Crown Advisors Management Inc. bought a new stake in Aytu BioPharma during the second quarter valued at about $430,000. Finally, Arete Wealth Advisors LLC bought a new stake in Aytu BioPharma during the first quarter valued at about $135,000. 33.49% of the stock is currently owned by institutional investors and hedge funds.
Aytu BioPharma News Roundup
These are some of the AYTU news items that stood out recently:
- Positive Sentiment: Rosemont agreed to acquire Aytu in an all-cash tender offer valued at $2.70 per share. The agreed price gives investors a defined cash consideration if the transaction closes, and Rosemont says the deal will support its U.S. expansion. Completion remains subject to the agreement’s conditions. Rosemont acquisition announcement
- Neutral Sentiment: Quarterly results were mixed: Aytu reported a loss of $0.20 per share, compared with a $0.08 loss a year earlier. Fiscal 2027 first-quarter results
- Neutral Sentiment: An investor-rights law firm announced an investigation into whether shareholders are receiving a fair price. The announcement is not a finding of wrongdoing, but adds a point of uncertainty around the transaction. Shareholder investigation announcement
Aytu BioPharma Company Profile
Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.
Featured Stories
- Five stocks we like better than Aytu BioPharma
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
